Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought OBMP purchased Avant Diagnostics with the exception of OVADX for 5B shares OBMP. That means OBMP went from a few million shares to 5B outstanding.
AMAZINGLY, the stock price barely dropped and is now taking off...?
As far as AVDX owners, I'm still waiting for my shares of OBMP.
From recent OBMP filing, Avant Diagnostics owns 5 billion shares of OBMP, which closed above $1 today.
Who owns Avant at this point?
Is this board alive and well, or is there another board for Avant Diagnostics.
When will the sticker start trading again
Does this mean anything for AVDX stock holders?
AVDX INVESTORS GROUP LLC
For the fiscal year ended September 30, 2017, we acquired a CLIA laboratory from THI. As a result of the cost cutting measures taken during the fiscal year ended September 30, 2017, the Company substantially curtailed the use of the CLIA laboratory. Also, as a result of these cost cutting measures, the Company was unable to timely make certain payments on the terms of the lease. As a result, the Company defaulted on its lease at the location of the Maryland laboratory and the landlord held the equipment located in the facility as collateral for amounts owed under the lease. AVDX Investors Group, LLC (“AVDX”), an entity controlled by Jeff Busch, our Executive Chairman (“Busch”), loaned the Company the capital to purchase the equipment. The note issued to AVDX is a demand promissory note that bears no interest and is secured by the equipment. During the fiscal year ended September 30, 2018, AVDX, Busch and his affiliated entities also loaned and/or paid certain obligations amounts on behalf of the Company.
————
????
https://www.sos.state.co.us/biz/ViewImage.do?masterFileId=20191479999&fileId=20191479999
https://www.sos.state.co.us/biz/BusinessEntityDetail.do?quitButtonDestination=BusinessEntityResults&nameTyp=ENT&masterFileId=20191479999&entityId2=20191479999&fileId=20191479999&srchTyp=ENTITY
Details
Name AVDX Investors Group, LLC
Status Good Standing Formation date 06/10/2019
ID number 20191479999 Form Foreign Limited Liability Company
Periodic report month June Jurisdiction Delaware
Principal office street address 1050 30th St NW STE 207, Washington D.C., DC 20007, United States
Principal office mailing address n/a
Registered Agent
Name Michael Irwin Ruxin
Street address 7558 S Turkey Creek, Morrison, CO 80465, United States
Mailing address PO BOX 869, Morrison, CO 80465, United States
Thanks for keeping up on current events. I haven't seen you on ARYC board for some time.
8K filed two days ago:
https://www.sec.gov/Archives/edgar/data/1451929/000149315219005062/form8-k.htm
It has now been 3 weeks since AVDX became current on their fins, yet they are still in the Grey Market. I hate to say, but it doesn't look good for them...
8K filed yesterday:
https://www.sec.gov/Archives/edgar/data/1451929/000149315219003925/form8-k.htm
10Q filed for quarter ending 31 Dec 2018 today:
https://www.sec.gov/Archives/edgar/data/1451929/000149315219003233/form10-q.htm
They are officially current!
Now to see if they will be released from the Grey Market.
I just checked out the 10Q for June 18 on AVDX, and I noticed they had $267,000 new cash. Where did that cash come from? Also, as you pointed out TSP, the net loss has been reduced by 7million, what happened there? Where did that money come from? When will it be time to buy shares on AVDX?
Still the stock price is soaring :)
If we only could say that about aryc as well!!! LOL
Once the file the 10-Q for 1st quarter ending 12/31/18 they will be current.
10K filed for quarter ending 30 Sep 2018 today:
https://www.sec.gov/Archives/edgar/data/1451929/000149315219002736/form10-k.htm
Net Loss on today’s AVDX 10K:
For the year ended September 30, 2018, we had a net loss of $2,371,797 compared to a net loss of $9,585,928 for the year ended September 30, 2017.
https://ih.advfn.com/p.php?pid=ihm_newsArtView&article=79380975&symbol=NO%5EAVDX&hl=1#FORM10-K_HTM_AB_007
New 8K filed today
https://seekingalpha.com/filing/4332503
This is the 10Q for Q3 2018. So once they file the 10K for fiscal year 2018 ending Sept 30 they will be current.
10Q filed for quarter ending 30 Jun 2018 today:
https://seekingalpha.com/filing/4318063
No idea, but I would think within the next month. Over the last 3 months, they have released 6 financial statements (or about 2 per month). The next filing due to be released should be for 30 Jun 2018.
Any estimate on the 3rd Q18 release date?
10Q filed for quarter ending 31 Mar 2018 yesterday:
https://seekingalpha.com/filing/4298292
FORM 10-Q For Quarter Ended: Dec 31, 2017 filed on Friday 12.28.18
What a mess the company is in!
https://www.sec.gov/Archives/edgar/data/1451929/000149315218018046/form10-q.htm
Its a total SCAM bro!! Dilution to the extreme BRO!! You got it!!! Yeah!!
Yes, I have noticed that as well.
The # of common shares seems to have been pretty steady over the last year:
26 Sep 2017: 303,927,098 (from 2Q2016 10Q)
7 Aug 2018: 336,957,722 (from 2016 10K)
29 Aug 2018: 336,957,722 (from 4Q2016 10Q)
10 Sep 2018: 336,957,722 (from 1Q2017 10Q)
28 Sep 2018: 336,957,722 (from 2Q2017 10Q)
30 Oct 2018: 336,957,722 (from 2017 10K)
But that 13G filing (from 25 May 2018) that lists over 1.4 billion shares is an outlier. I don't know what to make of it.
That same 13G shows Coastal Investment Partners as the reporting entity with 1.4 billion shares (6.4%) of common stock. But the most recent 10K (as of as of October 25, 2018) shows that Coastal owns 192,832 (10.77%) of Series A preferred stock shares (and not common shares). It doesn't show them owning ANY common stock.
Very confusing...`
Discrepancy in the number of outstanding common shares.
From the 13G filed
Filing Date 2018-10-26 for May 25, 2018 (Date of Event which Requires Filing of this Statement
Jun 2017 10Q & Sep 2017 10K were posted yesterday:
https://www.sec.gov/cgi-bin/browse-edgar?company=Avant+Diagnostics&owner=exclude&action=getcompany
Yup, looks that way.
Have no position or much knowledge of the company; just watching since ARYC owns shares, and the company may or may not still be involved with OvaDx and then there are a few subsidiaries of AVDX and products that may prove to be interesting.
it will be over soon.
May 25, 2018
(Date of Event which Requires Filing of this Statement)
https://www.sec.gov/Archives/edgar/data/1451929/000173112218000115/e1169_sc13g.htm
They planned to do a reverse split but haven't done so yet, otherwise share owners would have seen their shareholdings reduced substantially on their accounts.
My small baby sale triggered it to go up 200,000 percent
If a stock is not registered with the SEC and is Suspended the stock can remain on the Grey Market for years because there is/are no stock registration(s) to revoke. Market Makers are forbidden from making any market or quotations on all SEC Suspended stocks.
Banyan Gold, BYAGF, was never suspended by the SEC so it is on the Grey Market as a foreign Issuer and is merely waiting for FINRA to approve a Market Maker to represent the stock with quotations.
Two entirely different scenarios.
From my own personal experience, Banyan Gold (now BYAGF) was sent to the Gray Market years ago and still trades there, with an average volume of about 85,000. Not saying Grays are good, just sayin' it's not always the end of the world. :))
From reading this board there are serious misunderstandings about the imminent outcome for AVDX.
The SEC Admin. Law Judge will absolutely revoke Avant Diagnostics stock registration(s). When that occurs the ticker will no longer exist and the stock will no longer trade on any public market. AVDX shareholders will still own shares but in a private company, unable to trade any AVDX shares.
From the linked post the SEC Admin Law Judge revoked the registrations in 100% of all stocks that were suspended for severely delinquent Financials.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141911981
They did a R/S in May of 2018, which brought the number of O/S down to 15 million. After the private placement, the investors must have converted their preferred stock into common, as stated would happen in the PR, bringing the O/S count up to 337 million.
5/30/18
"Upon consummation of a reverse stock split of the Company's common stock, resulting in approximately 15,000,000 shares of the Company's common stock outstanding, the investors shall subsequently take all necessary steps with the Company to convert all outstanding shares of the Series A Preferred Stock into shares of the Company's common stock."
https://www.prnewswire.com/news-releases/avant-diagnostics-announces-restructuring-and-private-placement-300656180.html
I'm not sure what to think of that.
OTC reports 337 million (which is in line with the 10K) as of 1 N:
https://www.otcmarkets.com/stock/avdx/security
Paragraph 11 of the 13g:
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.4% (based on the total of 1,439,428,082 shares of Common Stock outstanding).
<< As of last May: Total of 1,439,428,082 shares of Common Stock outstanding >>
Where are you seeing this?
Their latest 10Q (for 317 Mar 2017) says:
Looks like they were suspended because they didn't update their address and didn't respond to the SEC letters:
Is AVDX still suspended to the Gray Market?
I don’t know many stocks that have rebounded so strongly from an unfortunate financial time like ARYC. There isn’t really anything to complain about when a company brings itself back over 10,000% with the potential to add even more zeros behind that number once current. Some people are just salty I guess
Guess someone missed out. Should have done more due diligence my friend and bought shares.
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1189
|
Created
|
04/15/15
|
Type
|
Free
|
Moderators |
March 7,2016
Avant Diagnostics (OTCQB: AVDX), a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), today announced that the companies have jointly entered into a letter of intent for Avant to acquire Theranostics Health Incorporated ("THI"), adding key CLIA laboratory and intellectual property capabilities to Avant and Amarantus' previously announced diagnostics merger. Theranostics currently generates over $1.5M in services revenue from some of the world's leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue.
Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.
OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.
As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market.
Investment Highlights
OvaDx®
The market's first large panel biomarker screening test for ovarian cancer
OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma.
Upon FDA approval, Avant Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1® and transvaginal ultrasound.
Clinicians will appreciate the following features of this product:
Ovarian Cancer
The Dire Need for Early Detection of the "Silent Killer"
Ovarian cancer is the 11th most common cancer among women and the fifth-leading cause of cancer-related death among women. According to the Centers for Disease Control, Ovarian cancer causes more deaths than any other cancer of the female reproductive system, but accounts for only about 3% of all cancers in women. When ovarian cancer is found in its early stages, treatment is most effective.
Often called "the silent killer," however, ovarian cancer is rarely caught early. Many times there are no symptoms until the disease has progressed to advanced stages. About 20% of ovarian cancers are found at an early, localized stage, and 94% of those patients live longer than five years after diagnosis, according to the American Cancer Society.
While regular women's health exams, knowledge of symptoms and risks, and screenings can be important ways to detect ovarian cancer, there is much research being done to develop new tests to accurately diagnose the disease at an early stage.
Management
Avant Diagnostics' progression toward FDA approval and commercialization of OvaDx® is spearheaded by a management team with a rich history of experience in executive leadership, accounting, corporate sales, marketing and financing for numerous industries.
Gregg Linn | President/CEO
Gregg Linn joined Avant Diagnostics as president and CEO in February December 2015. Prior to these roles, Linn served as the company's COO and CFO since December 2012. Since 2008, Linn served as the president and managing member of Issuers Capital Advisors, LLC, and since 2001 served as CEO and managing member of Red Rock Advisors, LLC. Both firms specialize in providing strategic financial and business development advisory services to public and non-public companies, with emphasis on capital formation, mergers and acquisition and management of the public side of small cap publicly traded companies. From 2004 to 2007, he was COO and CFO of Vital Living, Inc., a Phoenix, Arizona-based publicly traded nutritional supplements company. Prior to 2004, Linn served as CFO of several other public and privately held companies, senior financial management positions at Fortune 500 companies, as well as worked as a senior analyst at Shearson Lehman. Linn received an undergraduate degree in accounting and business from Michigan State University in 1984 and a Master Degree in Business Administration, summa cum laude, from Pace University-NYC in 1992. Linn is a certified public accountant.
Joseph Roth
Joseph Roth has spent more than three decades as a corporate sales, marketing and management executive with Fortune 50 companies as well as entrepreneur opportunities. For the past five years he has been self employed as a consultant to small and medium sized companies and C-level executives. From 2008-2010, he was COO of ShopBox, LLC, a business process outsourcing company specialized in the execution of web-based kiosk marketing strategies. He was responsible for securing partnership deals with NASCAR, NFL, NHL and NBA leagues, teams and franchises. From 2003 to 2008, Roth was president of CMB Franchising, Inc., a licensed Area Developer of Extreme Pita Restaurants of Canada for Arizona and Nevada. During this time he oversaw the construction, development and operations of 10 stores generating a 25% increase over the second highest volume franchise in the U.S. From 1996-2003, Roth was managing partner of Cypress Staffing Services, LLC, a company he founded in 1999 that provides private duty home care throughout Central Arizona. Cypress grew from scratch to become the largest company in Arizona within its industry category in less than four years.
Randall Letcavage
Randall Letcavage brings in excess of 25 years of business experience specializing in the financial markets, investment banking and business consulting. Currently, Letcavage is chairman, CEO, and president of Premier Holding Corp., which is publicly traded on the OTCQB exchange. For the past 20 years Letcavage has been an investment banker widely recognized for numerous achievements as well as his role of founder, officer and director of the iCapital Group, which includes iCapital Finance Inc, iCapital Advisory LLC and iCap Development LLC (A National "CDE" Community Development Entity – Certified by the U.S. Treasury Department). Letcavage has advised numerous clients on various transactions and financings in a wide range of industries, including technology, healthcare, financial services, entertainment, energy and green initiatives.
Avant Diagnostics, Inc | QualityStocks Investor Relations |
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Daily Chart
Weekly Chart
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |